Previous studies have demonstrated that CD103+CD8+ T cells might be a major cellular target of anti-PD-1 therapy in patients with melanoma and lung cancer.44,45 Our data strongly suggested that CD103+CD8+ T cell density could predict the effectiveness of checkpoint blockade in vitro. The gene discussed is ITGAE; the disease is lung carcinoma.